

Blujepa (gepotidacin)
Effective 05/01/2026

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	N/A		
Contact Information	Medical Benefit Pharmacy Benefit	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	N/A		

Overview

Blujepa (gepotidacin) is a triazacene naphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms:

- *Escherichia coli*
- *Klebsiella pneumoniae*
- *Citrobacter freundii* complex
- *Staphylococcus saprophyticus*
- *Enterococcus faecalis*

Blujepa is also indicated for the management of uncomplicated urogenital gonorrhea in adult and pediatric patients 12 years of age and older weighing at least 45 kilograms who have limited or no alternative treatment options.

Coverage Guidelines

If member is new to the plan (as evidenced by coverage effective date of less than or equal to 90 days), submission of medical records documenting that the member is currently receiving treatment with requested drug, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorization may be granted when all the following diagnosis-specific criteria are met:

Uncomplicated urinary tract infection (uUTI)

1. Diagnosis of uncomplicated urinary tract infection (uUTI)
2. Member has had a trial and inadequate response, contraindication, or resistance to one alternative oral antibiotic treatment option (e.g., ciprofloxacin, trimethoprim/sulfamethoxazole, nitrofurantoin)
3. Member's infection is caused by at least one of the following microorganisms:
 - a. *Escherichia coli*
 - b. *Klebsiella pneumoniae*
 - c. *Citrobacter freundii* complex
 - d. *Staphylococcus saprophyticus*
 - e. *Enterococcus faecalis*

Uncomplicated urogenital gonorrhea

1. Diagnosis of uncomplicated urogenital gonorrhea
2. Member has limited or no alternative treatment options, including ceftriaxone

Limitations

1. Approvals will be granted for 7 days
2. The following quantity limit applies:

Drug Name and Dosage Form	Quantity Limitation
Blujepa 750 mg tablet	20 tablets per fill

References

1. Biedenbach DJ, Bouchillon SK, Hackel M, et al. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. *Antimicrob Agents Chemother.* 2016;60(3):1918-23. doi: 10.1128/AAC.02820-15
2. Blujepa (gepotidacin) [prescribing information]. Durham, NC: GlaxoSmithKline; December 2025.
3. Gibson EG, Bex B, Chan PF, Osheroff N. Mechanistic and structural basis for the actions of the antibacterial gepotidacin against *Staphylococcus aureus* gyrase. *ACS Infect Dis.* 2019 Apr 12;5(4):570-581. doi: 10.1021/acsinfecdis.8b00315
4. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Disease. *Clin Infect Dis.* 2011;52:e103-e120. doi: 10.1093/cid/ciq257
5. Infectious Diseases Society of America (IDSA). IDSA practice guideline highlights and status. IDSA. 2025. Accessed April 21, 2025. <https://www.idsociety.org/practice-guideline/guideline-highlights/>
6. Kaye KS, Gupta V, Mulgirigama A, et al. Antimicrobial resistance trends in urine *Escherichia coli* isolates from adult and adolescent females in the United States from 2011 to 2019: Rising ESBL Strains and Impact on Patient Management, *Clin Infect Dis.* 2021;73(11):1992-1999.
7. Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. *Ther Adv Urol.* 2019;11:3-7. doi:10.1177/1756287219832172

Review History

11/12/2025 – Reviewed at November P&T. Effective 02/01/2026.

02/11/2026 – Reviewed and updated at February P&T. Added supplemental indication of gonorrhea. Updated approval length to 7 days. Effective 05/01/2026.

